p38-MAPK

p38 mitogen-activated protein kinase (MAPK) inhibitors act on stress-activated kinases of the MAPK family. In 1994 p38 was described as a kinase phosphorylated on tyrosine after exposure of cells to bacterial endotoxin or hyperosmolarity. In the same year, a kinase targeted by pyridinyl imidazole compounds was shown to regulate the biosynthesis of inflammatory cytokines. Adezmapimod, also known as SB 203580, and SB 202190 belong to this pyridinyl imidazole class and inhibit p38α and p38β. Doramapimod binds an allosteric pocket that becomes accessible in an inactive conformation of the kinase, a binding mode reported in 2002. PH-797804 and ralimetinib dimesylate are further p38α inhibitors for studies of inflammatory and stress signaling.

2 Items

  • NR-7h
    Cat. No.
    A40775

    NR-7h

    NR-7h is a selective degrader of p38α and p38β, exhibiting DC50 values of 24 nM and 27.2 nM for p38α in T47D and MB-MDA-231 cells, respectively. This compound effectively induces degradation of these kinases, facilitating the study of their roles in cellular signaling pathways. NR-7h is applicable in cancer research and other studies investigating inflammatory responses and signal transduction mechanisms.

    1 mg
    $335.00
    5 mg
    $455.00
    All 2 sizes
  • p38α inhibitor 5
    Cat. No.
    A40780

    p38α inhibitor 5

    p38α inhibitor 5 is a PROTAC-type ligand that specifically targets p38α MAP kinase. This compound is designed to facilitate the degradation of p38α, providing a valuable tool for studying the enzyme's role in cellular signaling and inflammation. It is suitable for applications in drug discovery and therapeutic research, particularly in the context of conditions associated with p38α dysregulation.

    5 mg
    $180.00
    10 mg
    $310.00
    All 5 sizes

2 Items

Added to your cart

View Cart Checkout

    Loading...